NeuroBo Pharmaceuticals, Inc. NRBO
2.36 0.00 (+0.00%)
At closeNov 27, 2024, 4:00 PM EST
2.36 Day range 2.36
52-week range unavailable
News
prnewswire.com NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming…
prnewswire.com NeuroBo Pharmaceuticals to Participate in Investor Conferences in November CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced…
prnewswire.com NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear…
prnewswire.com NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology…
prnewswire.com NeuroBo Pharmaceuticals to Participate in Investor Conferences in October CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced…
prnewswire.com NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate…
prnewswire.com NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced…
prnewswire.com NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based…
prnewswire.com NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from…
prnewswire.com NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals,…
prnewswire.com NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today…
prnewswire.com NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced…
247wallst.com Huge Insider Buying at a Warren Buffett Pick and 5 Other Stocks 24/7 Insights With the second quarter winding up, some insiders are making sizable purchases of stock.
prnewswire.com NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to…
prnewswire.com NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to…
prnewswire.com NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide Data Presented at the ADA 84th Scientific…
prnewswire.com NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone Data Will be Presented in Two Posters at the EASL Congress 2024 CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company…
prnewswire.com NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient…
prnewswire.com NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today…
prnewswire.com NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple…
benzinga.com Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
benzinga.com Stocks That Hit 52-Week Lows On Monday Monday's session saw 41 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 148 companies set new 52-week lows.
- benzinga.com Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket Gainers
benzinga.com Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session Gainers- benzinga.com Stocks That Hit 52-Week Lows On Friday OnFriday, 143 stocks hit new 52-week lows.
- benzinga.com Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
benzinga.com Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
benzinga.com Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday's Mid-Day Session Gainers Cosmos Holdings Inc. (NASDAQ: COSM) rose 68% to $0.5500 after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share.- benzinga.com Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday Gainers
- benzinga.com Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's…
benzinga.com Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday Gainers- benzinga.com Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session Gainers
- benzinga.com Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 184 companies set new 52-week lows.
- benzinga.com Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 236 companies set new 52-week lows.
- benzinga.com Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session Gainers
- benzinga.com Dow Surges 150 Points; US Economy Adds 261,000 Jobs U.S. stocks traded higher this morning, following the release of jobs data for the month of October.
- benzinga.com Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 85 stocks hit new 52-week lows.
- benzinga.com Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also…
benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers- benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers
benzinga.com Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.- benzinga.com Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
- benzinga.com Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.